Tags

Type your tag names separated by a space and hit enter

High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Int J Pharm. 2018 Oct 25; 550(1-2):398-417.IJ

Abstract

Tuberculosis (TB) is a major global health burden. The emergence of the human immunodeficiency virus (HIV) epidemic and drug resistance has complicated global TB control. Pulmonary delivery of drugs using dry powder inhalers (DPI) is an emerging approach to treat TB. In comparison with the conventional pulmonary delivery for asthma and chronic obstructive pulmonary disease (COPD), TB requires high dose delivery to the lung. However, high dose delivery depends on the successful design of the inhaler device and the formulation of highly aerosolizable powders. Particle engineering techniques play an important role in the development of high dose dry powder formulations. This review focuses on the development of high dose dry powder formulations for TB treatment with background information on the challenges of the current treatment of TB and the potential for pulmonary delivery. Particle engineering techniques with a particular focus on the spray drying and a summary of the developed dry powder formulations using different techniques are also discussed.

Authors+Show Affiliations

School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.School of Pharmacy, University of Otago, Dunedin 9054, New Zealand. Electronic address: shyamal.das@otago.ac.nz.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30179703

Citation

Momin, Mohammad A M., et al. "High Dose Dry Powder Inhalers to Overcome the Challenges of Tuberculosis Treatment." International Journal of Pharmaceutics, vol. 550, no. 1-2, 2018, pp. 398-417.
Momin MAM, Tucker IG, Das SC. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. Int J Pharm. 2018;550(1-2):398-417.
Momin, M. A. M., Tucker, I. G., & Das, S. C. (2018). High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. International Journal of Pharmaceutics, 550(1-2), 398-417. https://doi.org/10.1016/j.ijpharm.2018.08.061
Momin MAM, Tucker IG, Das SC. High Dose Dry Powder Inhalers to Overcome the Challenges of Tuberculosis Treatment. Int J Pharm. 2018 Oct 25;550(1-2):398-417. PubMed PMID: 30179703.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. AU - Momin,Mohammad A M, AU - Tucker,Ian G, AU - Das,Shyamal C, Y1 - 2018/09/01/ PY - 2018/06/05/received PY - 2018/08/30/revised PY - 2018/08/31/accepted PY - 2018/9/5/pubmed PY - 2019/1/8/medline PY - 2018/9/5/entrez KW - Dry powder inhaler KW - High dose KW - Particle engineering KW - Pulmonary delivery KW - Spray-drying KW - Tuberculosis SP - 398 EP - 417 JF - International journal of pharmaceutics JO - Int J Pharm VL - 550 IS - 1-2 N2 - Tuberculosis (TB) is a major global health burden. The emergence of the human immunodeficiency virus (HIV) epidemic and drug resistance has complicated global TB control. Pulmonary delivery of drugs using dry powder inhalers (DPI) is an emerging approach to treat TB. In comparison with the conventional pulmonary delivery for asthma and chronic obstructive pulmonary disease (COPD), TB requires high dose delivery to the lung. However, high dose delivery depends on the successful design of the inhaler device and the formulation of highly aerosolizable powders. Particle engineering techniques play an important role in the development of high dose dry powder formulations. This review focuses on the development of high dose dry powder formulations for TB treatment with background information on the challenges of the current treatment of TB and the potential for pulmonary delivery. Particle engineering techniques with a particular focus on the spray drying and a summary of the developed dry powder formulations using different techniques are also discussed. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/30179703/High_dose_dry_powder_inhalers_to_overcome_the_challenges_of_tuberculosis_treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(18)30649-5 DB - PRIME DP - Unbound Medicine ER -